Monthly Archives: September 2009

The October 2009 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:

Volume 15, Issue 4


Intellectual property and biotechnology innovation: To protect or not protect?PDF
Yali Friedman


The correlation between medical tourism and biotechnologyPDF
David G Vequist IV, Erika Valdez
The VC manifesto: Special pleading for a damaged cause: Commentary on Simon Witney interviewPDF
William Bains


Innovate America: The Technology Innovation Program at NISTPDF
Andrew S Klein, Mrunal S Chapekar
Valuation of complex license contractsPDF
Ralph Villiger, Boris Bogdan
How can pharmaceutical and biotechnology companies maintain a high profitability?PDF
Klaus J Nickisch, Joachim M Greuel, Kerstin M Bode-Greuel
Multiyear patterns regarding the relative availability of venture capital for the US biotechnology industryPDF
J Leslie Glick
Building biotechnology teams: Personality does matterPDF
Anne S York, Kim A McCarthy, Todd C Darnold
Beacon Sciences: Commercialisation from biothreat detection to beauty enhancementPDF
Rob Hanes, Damon Borich

Legal and Regulatory Updates

Legal and Regulatory UpdatePDF
Gerry Kamstra, John Wilkinson

Book Reviews

Book Review: Genomics & society: Legal, ethical and social dimensionsPDF
Dominic Clark
Book Review: Commercialization of innovative technologies: Bringing good ideas to the marketplacePDF
Arlen D Meyers
Book Review: Biotech funding trends: Insights from entrepreneurs and investorsPDF
J Leslie Glick

In these videos Pfizer’s Vice President and Global Head of Molecular Medicine, Aidan Power, talk about a future where everyone’s genome is sequenced and drug prescriptions are based on your genetic makeup, and argues that personalized medicine will be the defining paradigm for discovering and developing drugs of the future.

To put these videos into context, consider the recent report which found  that a majority of patients receiving Herceptin had not been tested for HER-2 overexpression — Herceptin is a targeted drug intended primarily for patients overexpressing HER-2. The apparently common prescription of Herceptin independent of it’s diagnostic test suggests that the practice of medicine needs to adapt to keep pace with scientific advance.

Vice President and Global Head of Molecular Medicine

Courtesy of

Drug Patent Expirations in September 2009

*Drugs may be covered by multiple patents

TradenameApplicantGeneric NamePatent NumberPatent Expiration
FARESTONGtx Inctoremifene citrate4,696,949Sep 29, 2009
FELBATOLMeda Pharmsfelbamate4,978,680Sep 26, 2009
FELBATOLMeda Pharmsfelbamate5,082,861Sep 26, 2009
GLUCOTROL XLPfizerglipizide5,024,843Sep 5, 2009
GLUCOTROL XLPfizerglipizide5,091,190Sep 5, 2009
IMPLANONOrganon Usa Incetonogestrel5,150,718Sep 29, 2009
NEORALNovartiscyclosporine5,866,159Sep 13, 2009
NEORALNovartiscyclosporine5,916,589Sep 13, 2009
NEORALNovartiscyclosporine5,962,014Sep 13, 2009
NEORALNovartiscyclosporine5,962,017Sep 13, 2009
NEORALNovartiscyclosporine6,007,840Sep 13, 2009
NEORALNovartiscyclosporine6,024,978Sep 13, 2009
PRIMAXINMerckcilastatin sodium; imipenem5,147,868Sep 15, 2009
STARLIXNovartisnateglinideRE34878Sep 8, 2009
TOBRADEXAlcondexamethasone; tobramycin5,149,694Sep 22, 2009
TOBRADEX STAlcondexamethasone; tobramycin5,149,694Sep 22, 2009
TOBRASONEAlconfluorometholone acetate; tobramycin5,149,693Sep 22, 2009
XALATANPharmacia And Upjohnlatanoprost6,429,226Sep 6, 2009

Courtesy of

This information is also available in an email newsletter: Subscribe to the DrugPatentWatch Patent Expiration Bulletin.